BSPM [Biostar Pharmaceuticals,] 10-K: (Original Filing)

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By | 2016-03-03T12:11:13+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: FORM 10-K (Mark One) x December 31, 2011

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By | 2016-03-03T12:12:52+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

EFUT [eFuture] 6-K: FOURTH QUARTER AND FISCAL YEAR 2011 EFUTURE ANNOUNCES

[FOURTH QUARTER AND FISCAL YEAR 2011 EFUTURE ANNOUNCES UNAUDITED FINANCIAL RESULTS Fourth quarter 2011 revenue rose 13% year-over-year, exceeding guidance BEIJING Fourth Quarter 2011 Financial Highlights . Total revenue increased 13% year-over-year to RMB83.3 million (US$13.2 million). . Gross profit decreased 23% year-over-year to RMB27.0 million (US$4.3 million). . Adjusted EBITDA was RMB8.9 million (US$1.4 million), compared to RMB10.6 million] [FORM 6-K eFuture Information Technology Inc. 8/F TopNew Tower 2 15 Guanghua Road Chaoyang District Beijing 100026,People's Republic of China 86-10-51650988 x o Form 20-F o x EFUTURE INFORMATION TECHNOLOGY INC. Adam Yan,]

By | 2016-04-01T05:25:36+00:00 March 27th, 2012|Categories: Chinese Stocks, EFUT, Webplus ver|Tags: , , , , , |0 Comments

CXDC [China XD Plastics Co] 8-K: (Original Filing)

[China XD Plastics Announces Fourth Quarter and Full Year 2011 Financial Results Reports Record Fourth Quarter and Full Year Revenues and Net Income - Launches Third Production Base with 90,000 MT Installed Annual Production Capacity - Announces Guidance for Fiscal Year 2012 - HARBIN, CHINA, March 26, 2012 – China XD Plastics Company Limited (NASDAQ: CXDC, "China XD Plastics" or] [______________ FORM 8-K ______________ TO SECTION 13 OR 15(d) OF March 26, 2012 Date of Report (Date of earliest event reported) CHINA XD PLASTICS COMPANY LIMITED Nevada 001-34546 04-3836208 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification No.) No. 9 Dalian North Road, Haping Road Centralized Industrial Park, Harbin Development Zone, Heilongjiang Province, PRC 150060 (86) 451-8434-6600 Not applicable]

By | 2016-03-25T16:01:52+00:00 March 27th, 2012|Categories: Chinese Stocks, CXDC, SEC Original|Tags: , , , , , |0 Comments

CXDC [China XD Plastics Co] 8-K: China XD Plastics Announces Fourth Quarter and Full

[China XD Plastics Announces Fourth Quarter and Full Year 2011 Financial Results Reports Record Fourth Quarter and Full Year Revenues and Net Income - Launches Third Production Base with 90,000 MT Installed Annual Production Capacity - Announces Guidance for Fiscal Year 2012 - HARBIN, CHINA, March 26, 2012 – China XD Plastics Company Limited (NASDAQ: CXDC, "China XD Plastics" or] [______________ FORM 8-K ______________ TO SECTION 13 OR 15(d) OF March 26, 2012 Date of Report (Date of earliest event reported) CHINA XD PLASTICS COMPANY LIMITED Nevada 001-34546 04-3836208 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification No.) No. 9 Dalian North Road, Haping Road Centralized Industrial Park, Harbin Development Zone, Heilongjiang Province, PRC 150060 (86) 451-8434-6600 Not applicable]

By | 2016-03-25T16:03:28+00:00 March 27th, 2012|Categories: Chinese Stocks, CXDC, Webplus ver|Tags: , , , , , |0 Comments

SOL [ReneSola] 6-K: (Original Filing)

[ReneSola Appoints President of China Division JIASHAN, China, March 26, 2012 ReneSola CEO Mr. Xianshou Li remarked, “While China leads the world in the number of solar panels exported, it lags behind many countries in terms of the number of solar panels installed. This is changing, however, and we believe the Chinese market has impressive growth prospects. In 2012, we] []

By | 2016-03-27T11:35:25+00:00 March 27th, 2012|Categories: Chinese Stocks, SEC Original, SOL|Tags: , , , , , |0 Comments

SOL [ReneSola] 6-K: ReneSola Appoints President of China Division JIASHAN, China,

[ReneSola Appoints President of China Division JIASHAN, China, March 26, 2012 ReneSola CEO Mr. Xianshou Li remarked, “While China leads the world in the number of solar panels exported, it lags behind many countries in terms of the number of solar panels installed. This is changing, however, and we believe the Chinese market has impressive growth prospects. In 2012, we] []

By | 2016-03-27T11:36:42+00:00 March 27th, 2012|Categories: Chinese Stocks, SOL, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar